회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 화학/신소재 > 화학
Investigation Report on China Megestrol Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-05
분량 30 pages
서비스형태 Report
판매가격

인쇄하기

Description

Nowadays, breast cancer has the highest incidence among malignancy for women all over the world. According to the statistics released by World Health Organization (WHO), the number of breast cancer cases around the world reaches 1.2 million per year while a global death toll is about 0.5 million per year. In the past decade, the annual growth rate of the incidence of breast cancer hit 8%. By 2020, the incidence of cancer will increase by 50% and the number of new cases of cancer around the world will reach 15 million per year.
In recent years, the growth rate of the incidence of breast cancer in China ranks first in the world with one in ten women suffering from breast cancer. In 2015, the number of new cases of breast cancer in China has surpassed that of the US and become the largest in the world. In 2014, the number of newly confirmed cases of breast cancer was 0.225 million, increasing sharply by 50% compared with 2004. At the same time, nearly two thirds of newly confirmed cases can survive for more than 20 years with a long-term survival rate rising sharply by 20%. According to WTO, this astonishing progress benefits from the discovery and sale of new drugs with better efficacy and fewer adverse reactions.
About two thirds of breast cancer patients use hormone therapy. Common varieties of progestin are medroxyprogesterone and megestrol which act by blocking the source of human estrogen with an unsatisfactory efficacy rate of 30%-50%. Since their efficacy is not better than other drugs for breast cancer and their price is relatively high, their sales is not very big. But according to the latest domestic reports, progestin occupies nearly 2% of clinical medication for breast cancer with rising sales. After entering Chinese market, Megestrol develops very fast. Although its sales in 2011 underwent a small decline, it still enjoys an obvious growth trend in recent years. The annual sales of megestrol rose from CNY 29.95 million in 2010 to CNY 37.22 million in 2014 with a compound growth rate of 5.58%.

Readers can get at least the following information through this report:
-market size of megestrol in China
-major manufacturers of megestrol for Chinese market and their market share
-retail price of megestrol in Chinese market
-market outlook of megestrol in China

The author suggests the following groups of people purchase this report:
-manufacturers of progestin
-investors/ research institutions interested in Chinese medicine market
-any interest in medicine market in China, please contact CRI for customized survey service


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.